<table>
<thead>
<tr>
<th>項目</th>
<th>内容</th>
</tr>
</thead>
<tbody>
<tr>
<td>タイトル</td>
<td>A RAT MODEL OF HTLV-I INFECTION : I. Humoral antibody response, provirus integration and HAM/TSP-like myelopathy in seronegative HTLV-I carrier rats</td>
</tr>
<tr>
<td>著者</td>
<td>石黒 信久</td>
</tr>
<tr>
<td>招致機関</td>
<td>北海道大学 博士 醫学 [乙第 4236号]</td>
</tr>
<tr>
<td>発行日</td>
<td>1993-03-25</td>
</tr>
<tr>
<td>DOI</td>
<td>10.11501/3071565</td>
</tr>
<tr>
<td>URL</td>
<td><a href="http://hdl.handle.net/2115/32607">http://hdl.handle.net/2115/32607</a></td>
</tr>
<tr>
<td>種類</td>
<td>theses (doctoral)</td>
</tr>
<tr>
<td>註</td>
<td>共著者あり。共著者名: Abe Masakazu, Seto Kazutoshi, Sakurai Hiroharu, Ikeda Hitoshi, Wakisaka Akemi, Togashi Takehiro, Tateno Masatoshi, Yoshiki Takashi.</td>
</tr>
<tr>
<td>ファイル情報</td>
<td>4236.pdf</td>
</tr>
</tbody>
</table>
A RAT MODEL OF HTLV-I INFECTION

1. Humoral antibody response, provirus integration and HAM/TSP-like myelopathy in seronegative HTLV-I carrier rats

学位論文

ヒト T 細胞白血病ウイルス感染ラットモデル
1. 抗HTLV-I液性抗体反応、プロウイルスゲノムの臓器分布、抗体陰性持続感染ラットにおけるHAM/TSP 様病変の発症

小児科学講座

石黑 信 久
A RAT MODEL OF HTLV-I INFECTION

I. Humoral antibody response, provirus integration and HAM/TSP-like myelopathy in seronegative HTLV-I carrier rats

Nobuhisa ISHIGURO,* § Masakazu ABE,* Kazutoshi SETO,* Hiroharu SAKURAI,* Hitoshi IKEDA,* Akemi WAKISAKA,* Takehiro TOGASHI, §
Masatoshi TATENO,** and Takashi YOSHIKI*

* Department of Pathology, § Department of Pediatrics, Hokkaido University
School of Medicine,** Department of Pathology, Sapporo City General Hospital, Sapporo, Japan

Running title: A Rat Model of HTLV-I Infection

Address correspondence to Dr. Takashi Yoshiki, Department of Pathology, Hokkaido University School of Medicine, Kita-15 Nishi-7, Kita-ku, Sapporo 060, Japan. FAX 011-758-4127, PHONE 011-758-4127
SUMMARY

HTLV-I can be transmitted into several inbred strains of newborn and adult rats by inoculating newly established HTLV-I immortalized rat T cell lines or the human T cell line, MT-2. The transmission efficiency exceeds 80%, regardless of strain differences or the age at transmission. The production of anti-HTLV-I antibodies significantly differs among the strains and depends on the age at the time of transmission. Rats neonatally inoculated with HTLV-I positive rat or human cells generally become seronegative HTLV-I carriers throughout their lives, whereas, adult rats inoculated with HTLV-I positive cells at 16 weeks of age become seropositive HTLV-I carriers. The HTLV-I provirus genome is present in almost all organs, regardless of whether the carriers are seronegative or seropositive. According to antibody titers to HTLV-I, inbred rat strains can be grouped into 3; ACI, F344, and SDJ as high responders; WKA, BUF, and LEJ as intermediate responders; and LEW as low responders. Three out of 3 16 month old seronegative HTLV-I carrier rats of the WKA strain developed spastic paraparesis of the hind legs. Neuropathological examinations revealed that the lesions were confined primarily to the lateral and anterior funiculi of the spinal cord. Both myelin and axons were extensively damaged, in a symmetrical fashion and infiltration with massive foamy macrophages was evident. The most severe lesions were at levels of the thoracic cord and continued from the cervical to the lumbar area. These histopathological features as well as clinical symptoms largely parallel
findings in humans with HTLV-I associated myelopathy/tropical spastic paraparesis (HAM/TSP). These HTLV-I carrier rats, in particular the WKA rats described above can serve as an useful animal model for investigating virus-host interactions in the etiopathogenesis of HTLV-I related immunological diseases, particularly HAM/TSP.
INTRODUCTION

The human T lymphotropic virus type I (HTLV-I), which was first isolated and characterized from a patient with cutaneous T cell lymphoma [1], is distinct from other human viruses and from animal retroviruses, in nucleic acids [2], major core proteins [3], and reverse transcriptase [4]. Further extensive study showed that HTLV-I is the oncogenic agent of adult T cell leukemia (ATL)[5]. It was reported that HTLV-I infection is also related with immunological diseases such as HTLV-I associated myelopathy/tropical spastic paraparesis (HAM/TSP) [6,7,8,9], HTLV-I associated bronchopneumopathy (HAB) [10], HTLV-I associated arthropathy (HAAP) [11] and Sjögren syndrome [12]. To analyse mechanisms involved in the development of these diseases, an animal model would be useful. HTLV-I has been reported to have immortalizing effects on human [13], simian [14], cat [15] and rabbit [16] lymphocytes. Yoshiki and colleagues found that HTLV-I can infect and immortalize rat T cells, in vitro [17,18]. They [19] and Suga et al. [20] suggested that HTLV-I can be transmitted into WKA and F344 rats, in vivo.

We have now transmitted HTLV-I into several inbred strains of newborn and adult rats, and strain differences in humoral antibody responses against HTLV-I and tissue distribution of the HTLV-I provirus genome were investigated. Development of HAM/TSP-like myelopathy in HTLV-I carrier rats was also monitored. This is the first description of an animal model for the HAM/TSP which occurs in humans.
Materials and methods

Cell lines

Four HTLV-I immortalized rat cell lines, LEWIS-S1, WKA-S1, F344-S1 and ACI-S1, were newly established by cocultivating spleen cells of four inbred rats of LEW/Hkm(LEW), WKA/Hkm(WKA), F344/Slc(F344) and ACI/Hkm(ACI) strain with ATL cells from a typical ATL patient after treating them with 5-bromo-2'-deoxyuridine (BrdUrd), as described elsewhere [17]. The cells were maintained in RPMI 1640 supplemented with 10% heat-inactivated FCS, penicillin(100 IU/ml), streptomycin(100 μg/ml), and were free from exogenous IL-2.

The HTLV-I-producer human cell line, MT-2 was kindly provided by Dr. I. Miyoshi, Department of Medicine, Kochi Medical College, Kochi, Japan [13].

Antibodies

RTH-7, R1-3B3 and R1-10B5 were mAbs that reacted with the rat homologs of CD4, CD5 and CD8, respectively, and were generously provided by Drs. A. Matsuura and K. Kikuchi, Sapporo Medical College, Sapporo, Japan [21,22]. Anti-Leu 3a (Becton Dickinson, CA, USA) and ART 18 [23] (Boehringer Mannheim, Mannheim, Germany) were the mAbs used against human CD4 and rat IL-2 receptor, respectively. Polyclonal antibodies against rat and human Ig were purchased from Organon Teknika corp., NC, USA.
Animals and transmission of HTLV-I

Inbred female WKA, LEW, ACI, SDJ/Hkm(SDJ), BUF/Hkm(BUF) and LEJ/Hkm(LEJ) rats were obtained from the Institute for Animal Experiments, Hokkaido Univ. School of Medicine, Sapporo, Japan. Inbred female F344 rats were purchased from SLC Japan (Shizuoka, Japan).

Ten million cells of LEWIS-S1 and WKA-S1, which were treated with Mitomycin C (MMC, Kyowa Hakko, Co., Tokyo, Japan) at a concentration of 25 mg/ml for 30 minutes at 37°C, were inoculated into the peritoneal cavity of newborn LEW and WKA rats within 24 hours after birth, respectively. 1 x 10^7 cells of MT-2 were inoculated into the peritoneal cavity of newborn LEW, WKA, F344 and ACI rats within 24 hours after birth. One x 10^7 cells of MT-2 were injected into the tail vein of 16 week-old LEW, WKA, F344, ACI, SDJ, BUF and LEJ rats twice, at two week intervals. HTLV-I infected rats were maintained under the P3 level.

To identify the anti HTLV-I antibody and HTLV-I provirus genome, peripheral blood was taken from the tail vein.

Detection of antibodies against HTLV-I antigens

The titer of antibody against HTLV-I antigens in the serum and cerebrospinal fluid (CSF) was determined by the particle agglutination test (SERODIA • HTLV-I, Fuji Rebio Inc., Tokyo, Japan).
Polymerase Chain Reaction

DNA was isolated from Ficoll-Paque separated PBMCs or organ tissues using SDS and proteinase K methods [24]. Polymerase chain reaction (PCR) was carried out as described [25]. Briefly, 0.5 μg of extracted DNA was subjected to 35 cycles of PCR amplification using Taq polymerase (Takara Shuzo Co., Kyoto, Japan); 94°C over one minute, 58°C over two minutes, 72°C over three minutes. The primers were 5’-2328 GCCAAACCCAAGATCAC TTTAAGC 2351-3’ (sense) and 3’-2588 GGAAATTTGCTCTTGCAGGAG 2607-5’ (anti-sense) for pol region amplification (Synthetic Genetics Inc., CA, USA), and 5’-7358 CGGATACCCAGTCTACGTGT 7377-3’ (sense) and 3’-7516 GCTA CCTGCAGATAGCCGAG 7496-5’ (anti-sense) for pX region amplification [26]. Each PCR product was electrophoresed on a 2% agarose gel and transferred to nylon membrane. The membrane was hybridized with radioactively labelled oligonucleotide probes; 3’-2498 CGTTTTCCCGGCAGGAC ATTAGAACCGGTATGTCCGCGGTC 2537-5’ (anti-sense) for pol region and 3’-7447 AGGTGATCTGATGCTCTGGACAGGTGGCCAGTAGGGCG 7486-5’ (anti-sense) for pX region. The membrane was washed in 2x SSC, 0.2% SDS at room temperature for 15 minutes, twice, and in 0.2x SSC, 0.2% SDS at 55°C for 15 minutes, twice. The specific amplified bands were detected by exposure to Kodak XAR film at -70°C. For the standard control, the detection limit of the PCR was up to 5^{-6}. 
Light microscopy

In addition to routine hematoxylin and eosin (HE) stain, Luxol fast blue (LFB), Bodian and Holzer stains were employed.
Results

Characterization of newly established HTLV-I immortalized rat T cell lines

In four newly established HTLV-I immortalized rat cell lines, it was confirmed that at least one full length of HTLV-I provirus genome was integrated, transcribed and expressed, using Southern, Northern and Western Blots analyses, respectively. Analyses of cell surface markers showed these cell lines to be positive for rat CD4 and CD5 and were negative for rat CD8 and human markers. They also expressed the rat IL-2 receptor. The results are summarized in Table 1. Morphologically, nuclear polymorphism resembling ATL cells was seen in a large proportion of WKA-S1 and ACI-S1 cells. The other cell lines also contained cells with nuclear polymorphism, albeit to a lesser extent. Only in the ACI-S1 cell line were extracellular type C virus particles sometimes evident, as seen electron microscopically.

Infectious transmission of HTLV-I into newborn and adult rats

LEWIS-S1 and WKA-S1 cells were injected into newborn LEW and WKA rats. Purified DNA from peripheral blood mononuclear cells (PBMCs) was subjected to PCR amplification, using both pol and pX primers. Samples in which PCR results were positive for both pol and pX primers were considered to be positive. The HTLV-I provirus genome was evident in PBMCs from 16 of 18 LEW rats, and all of 3 WKA rats at 4 ~ 6 months postnatally (Table 2). We considered that LEWIS-S1 and WKA-S1 cells
produced HTLV-I virus and had infectivity potential for the newborn rats, however, antibodies against HTLV-I were never detected in these rats at 1 - 7 months after birth. When MT-2 cells were injected into newborn LEW, WKA, F344 and ACI rats, the HTLV-I provirus genome was detected in PBMCs from all of 8 LEW rats (100%), 8 of 9 WKA rats (89%), 16 of 20 F344 rats (80%) and 7 of 8 ACI rats (88%). Only 2 of 16 F344 rats seroconverted for anti - HTLV-I antibodies, the titers being between 1:8 and 1:16. None of the other rats had anti - HTLV-I antibodies (Table 2).

When MT-2 cells were injected intravenously into seven different strains of adult rats, all 5 (100%) in each strain (except for F344, only one rat was tested) carried the HTLV-I provirus genome in their DNA extracted from PBMCs 4 months after injection (Table 3). Anti - HTLV-I antibodies were detected in all these rats as early as 3 weeks after injection, and the titers ranged between 1:8 and 1:8192 thereafter. The specificity of these antibodies against HTLV-I antigen was confirmed by evidence of HTLV-I specific gag proteins (p19, p24, p53), obtained using Western Blots (data not shown).

**Humoral immune response against HTLV-I**

Humoral antibody response against HTLV-I was compared. Adult LEW, WKA, F344, ACI, SDJ, BUF and LEJ rats were given intravenous injections of $1 \times 10^7$ MT-2 cells, twice, as described above, and anti - HTLV-I antibodies in the sera were measured at 2, 3, 7, 13, 21, 28, 40 and 49 weeks after the first injection. As shown in Figure 1, the antibodies were detectable as early
as 2 ~ 3 weeks after the injection and a plateau was reached at 12 weeks. Antibody titers tended to decline slightly after 28 weeks but were maintained high at 49 weeks. ACI and SDJ rats were considered to be high responders, as the titer of anti-HTLV-I antibodies was higher than did other strains, and LEW rats were low responders, with low anti-HTLV-I antibodies. F344 rats produced a high level of anti-HTLV-I antibodies for up to 13 weeks after the first injection. Further measurement of anti-HTLV-I antibody was done in only one of F344 rats maintaining a high level of antibody titer of 1:4096 at 28 weeks. The F344 strain was thus considered to be a high responder, like the ACI and SDJ strains. Rats of the other three strains produced anti-HTLV-I antibodies with intermediate titers, and were classed as intermediate responders. The difference in humoral response against HTLV-I is statistically significant. (t-test)

Tissue distribution of the HTLV-I provirus genome

Five female F344 rats injected with MT-2 cells in the neonatal period, were killed at age 50 weeks. DNAs extracted from PBMCs and tissues from each organ were subjected to PCR amplification, using pX primers. Each DNA sample was PCR analyzed more than twice, and the sample in which the HTLV-I provirus genome was reproducibly demonstrated, was judged as positive. The HTLV-I provirus genome was detected in almost all organs examined, including the thymus (5/5), kidney (5/5), spleen (4/5), submandibular gland (4/5), lymph nodes (5/5) and PBMCs (5/5) (Table 4). PCR result is shown in Figure 2.
Development of HAM/TSP-like myelopathy

Eight of 9 WKA rats neonatally inoculated with MT-2 cells became HTLV-I carriers yet had no detectable anti-HTLV-I antibodies (Table 2). Four rats were killed at age of 4 months and tissue distribution of provirus genomes was examined. One of the remaining 4 male rats died at age 12 months of unknown causes and autopsy was not done. At age 16 months, 2 of 3 rats were first seen to have spastic paraparesis of the hind legs and 2 weeks later, the remaining had similar symptoms. The spastic paraparesis progressed within 3 months and all 3 rats could hardly move because of the muscular atrophy of the hind legs. A most severely affected rat, WKA #54 and a moderately affected rat, WKA #57 were histologically examined. Provirus genomes in the central nervous system (CNS) tissues as well as in the PBMCs, and anti-HTLV-I antibodies in the serum and CSF were also examined. The remaining one was found dead and autopsy was not done. Macroscopically, the brains of both rats appeared normal. The spinal cord of WKA #54 showed slight atrophy, particularly in the thoracic region while that of #57 appeared to be normal. On microscopic examination of #54, both myelin and axons in the lateral and anterior funiculi were extensively damaged, in a symmetrical fashion and were infiltrated with abundant foamy macrophages (Fig. 3A,B,C,D). Marked vacuolar changes were observed, however, slight vacuolar changes were also observed in the age-matched untreated controls. The lesion developed preferentially in the lateral and anterior funiculi, and apparently to a lesser extent in the posterior funiculi. The most severe lesions were at levels of the thoracic cord, they continued
from the cervical to the lumbar cord and were localized in the outer portion of the funiculi. The schematic distribution of the affected lesion in the spinal cord is shown in Fig. 3E. The inner portion of the funiculi and central gray matter appeared intact. Lymphocytic infiltration was virtually absent in the white and gray matter, or in the perivascular areas throughout the entire spinal cord. Fibers of the anterior and posterior roots of the severely affected cord also showed loss of myelin and axons with infiltration of foamy macrophages. There appeared to be no neuronal degeneration in the anterior horn cells, cells of Clark's column, or any nuclei.

Loss of myelin or axonal degeneration was not seen in the cerebrum, the cerebellum, and the brain stem above the level of the medulla oblongata. Perivascular cuffings with lymphocytes were not observed. Atypical lymphocytes were absent in the brain and spinal cord. Muscle of the hind legs showed severe group atrophy without inflammatory reaction. Other organs were histologically normal. Pathological findings of WKA #57 were essentially the same as those in #54 with loss of myelin and axons and infiltration of foamy macrophages in the lateral and anterior funiculi. Although severity of the affected lesions was less pronounced than that of #54, levels of the thoracic cord were preferentially damaged (Fig. 3E). Lymphocytic infiltration was not observed. Anti-HTLV-I antibodies in the sera of #54 and #57 and CSF of #54 were negative. CSF of #57 could not be collected. The HTLV-I provirus genome was evident in the PBMCs, cerebrum and in the spinal cord of #57 by PCR amplification. The spinal cord of #54 was not examined.
DISCUSSION

Several observations presented in this paper lead to the conclusion that the inbred rat provides a useful animal model for HTLV-I infection in man. In 1984, we reported that HTLV-I infected and immortalized rat T cells of the spleen, lymphnodes, and thymus, when cocultivated with BrdUrd-treated ATL cells [17]. In the present study, by inoculating newly established rat T cell lines or a human T cell line, MT-2, we succeeded in establishing HTLV-I carriers in several inbred strains of newborn and adult rats, as determined by virus genome integration. We found no strain differences in the susceptibility to HTLV-I virus infection in neonates and transmission efficiency exceeded 80%. Adult rats of several different strains are equally susceptible to HTLV-I infection. Newborn HTLV-I carriers, in general, show an unresponsiveness in humoral antibody response to HTLV-I throughout their life span. However, this unresponsiveness can be easily broken down, since a secondary challenge of MT-2 cells at age 7 months leads to the production of anti-HTLV-I antibodies with antibody titers of 1 : 256 to 1 : 512, as tested 1 month later (unpublished). Adult HTLV-I carriers continuously produce humoral antibodies to HTLV-I, similar to those in humans. According to antibody titers against HTLV-I, inbred rat strains can be grouped into 3; ACI, F344, and SDJ as high responders; WKA, BUF, and LEJ as intermediate responders; and LEW as low responders. In human carriers, there are high and low responders to HTLV-I, as possibly related to particular HLA haplotypes, the former is likely to become HAM/TSP [27].
Therefore, strain difference in the humoral antibody response to HTLV-I in the rat provides useful information for future research.

Three out of 3 newborn HTLV-I carriers of the WKA strain developed spastic paraparesis of the hind legs, at age 16 months. Clinical symptoms and neuropathological findings generally mimic those of HAM/TSP seen in humans [6,7,8,9,28,29,30]. The lesions are primarily confined to the lateral and anterior funiculi of the spinal cord. The most severe lesions are levels of the thoracic cord, and continue from the cervical to the lumbar cord. Both myelin and axons are extensively damaged, in a symmetrical fashion and are infiltrated with massive foamy macrophages. Newborn and adult carriers of other strains have not developed neurological disease clinically and pathologically. Thus, HTLV-I carriers of WKA strain are suitable models for the HAM/TSP in humans. The WKA/Hkm rats, formerly called Wistar-King-Aptekman rats are agouti (A/A), coat color (B/B), albino (c/c); h and have been typed for the following polymorphic loci: Akp-1a, Alp-a, Cs-b, Es-1a, Es-2a, Es-3a, Es-4b, Es-7b, Es-8b, Es-9a, Es-10a, Essb, Fh-1b, Gst-1b, Hao-1a, Hbbb, Mdl-1a, Pgd-b, Rtl1k, Sup-1a, Tam-1b [31, 32]. Since HAM/TSP occurs with increased frequency with certain HLA haplotypes [27], the genetic background of WKA, especially R T 1 k haplotype of rat MHC may be one of critical host factors determining disease susceptibility. Further investigations are necessary to clarify this point.

Retrovirus-induced neurological disease has been recognized for many years in animals. Among them, retroviral spongiform polioencephalomyelopathy in wild mice [33,34,35] and visna in sheep [36,37,38] have been
most extensively studied. From animal studies, there is evidence that retroviral infection can damage the CNS tissue via either immunological mechanisms or through a direct neurotropic effect of the retrovirus. The intense lymphocytic infiltration in the affected lesion and perivascular areas of the spinal cord, the presence of IgG and IgM oligoclonal bands in the CSF, some of which are directed against HTLV-I, the high titer of antibodies to HTLV-I, and the therapeutic effectiveness of high dose steroid are all consistent with an immune hypothesis of the CNS tissue damage in HAM/TSP [7,8,9,28,29,30]. However, the mechanism of CNS tissue damage in HAM/TSP still remains virtually unknown. There are at least three essential points to stress about these diseased rats, tentatively designated as "HAM rats". First, HAM rats produce no detectable antibodies to HTLV-I in the CSF or in the serum. As already mentioned, HAM/TSP patients are usually associated with high titered antibodies to HTLV-I in both the CSF and serum [7,9]. Humoral antibody response to HTLV-I may not play a major role, if any, in the pathogenesis of HAM/TSP in humans. Production of humoral antibodies to HTLV-I in the CNS of HAM/TPS patients might be a self-protecting reaction or merely a secondary phenomenon. Second, in contrast to the affected spinal cord in HAM/TSP patients [28,29,30], HAM rats show no lymphocytic infiltration in the white or gray matter, or in the perivascular areas throughout the whole spinal cord. Foamy macrophages predominantly infiltrate the affected lesion. Visna is a slow retrovirus infection of sheep which produces both inflammatory and demyelinating lesions of the CNS. Although the pathogenesis of the CNS lesions is still
unclear, host factors in virus susceptibility and immune mechanisms undoubtedly play pathogenic roles [37,38,39,40,41]. Sheep experimentally infected by intracerebral inoculation of visna virus are apparently healthy but at autopsy many show an inflammatory exudate throughout the CNS and meninges within weeks [37]. In the spinal cord, there is a marked histological difference in the affected lesions of early and advanced stage of the disease [42]. At an early stage, the main pathological changes are inflammatory reactions consisting of lymphocytes, macrophages and some plasma cells. In advanced lesions, demyelinating foci closely associated with clinical paresis occur and inflammation is minimal or absent. Since the initial stage of rat HAM has not been examined, it is too early to conclude with certainty that lack of lymphocytic infiltration in the affected lesions is a characteristic pathologic feature of rat HAM. Whether the absence of lymphocytic infiltration in the affected lesion reflects stage of the disease process, species difference in the host response between rat and man, or non-immunological demyelination in the pathogenesis of rat HAM remains to be determined. Third, HTLV-I provirus genome was clearly demonstrated by PCR in the spinal cord and cerebrum as well as PBMCs of a HAM rat #57. The precise localization of provirus genome, whether it localizes in the damaged spinal cord tissue, in the infiltrating macrophages, or in the blood-born or hidden lymphocytes carrying HTLV-I will remain to be determined. Neither integration of provirus genome, nor expression of mRNA and viral proteins of HTLV-I has been confirmed in the diseased CNS tissues of HAM/TSP patients [29,43]. Therefore, there is no direct proof
that the inflammation and tissue damage in the spinal cord of HAM/TSP patients is a consequence of viral infection in the CNS tissue. Determination of in situ localization of provirus genome, mRNA and viral proteins in the affected spinal cord of HAM rat would be of critical importance for investigating pathogenic roles of HTLV-I in the disease mechanism of HAM/TSP in humans.

In conclusion, this is the first description of a rat model for HAM/TSP in humans. This model is expected to contribute to a better understanding of mechanisms involved in the etiopathogenesis of HTLV-I related immunological diseases in man, particularly HAM/TSP.
ACKNOWLEDGEMENTS

We thank Drs. I. Miyoshi, A. Matsuura, K. Kikuchi and M. Hatanaka for providing MT-2 cells, monoclonal antibodies and HTLV-I probe, Ms. M. Yano and Dr. H. Ikeda for examination of the anti-HTLV-I antibodies, Mr. T. Osanai and all staff of Institute for Animal Experiment, Hokkaido Univ. School of Medicine, for maintenance of infected rats, Ms. C. Sudo for technical assistance of histopathological examinations and Ms. M. Ishizaka for secretarial assistance. We also thank Dr. S. Matsumoto and M. Ohara for critical reading of the manuscript and Dr. K. Nagashima for useful discussion of the neuropathological findings.

This study was supported in part by grants from the Ministry of Education, Health and Welfare, and Science and Technology of Japan.
REFERENCES


FIGURE LEGENDS

Fig. 1 Strain differences in anti - HTLV-I antibody production in rats. Results represent mean titer±SD. Differences in response against HTLV-I are statistically significant (t-test) ; * P< 0.05, ** P< 0.01. *** Number of rats examined is given in parenthesis.

Fig. 2 Tissue distribution of the HTLV-I provirus genome, using PCR and pX primers in F344 rat, #130. The positive control is cloned LEWIS-S1 cells and the negative control is PBMCs of a normal rat.

Fig. 3 Histopathological findings and schematic distribution of the affected lesion in the spinal cord of HAM rats. A&B(x30); Symmetrical distribution of the damage in the white matter is shown, as a whole view of the affected thoracic cord (#54, Th7). C&D(x140); Vacuolar degeneration, demyelination and infiltration of foamy macrophages are evident in the enclosed area of A. Distribution of affected lesions in spinal cords of #54 and #57 are represented in schematic figure (E). The solid area shows severe damage and the hatched area a lesser degree of damage. No marked change was found in the blank area, as compared with age-matched untreated control. A, C; HE stain, B, D; LFB stain.
<table>
<thead>
<tr>
<th>Cell line</th>
<th>Rat marker *</th>
<th>Human marker *</th>
<th>HTLV-I</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>CD5</td>
<td>CD4</td>
<td>CD8</td>
</tr>
<tr>
<td>Lewis - S1</td>
<td>+</td>
<td>+</td>
<td>-</td>
</tr>
<tr>
<td>F344 - S1</td>
<td>+</td>
<td>+</td>
<td>-</td>
</tr>
<tr>
<td>WKA - S1</td>
<td>+</td>
<td>+</td>
<td>-</td>
</tr>
<tr>
<td>ACI - S1</td>
<td>+</td>
<td>+</td>
<td>-</td>
</tr>
</tbody>
</table>

* Cell surface markers were detected by indirect immune fluorescence using FACScan (Becton Dickinson, CA, USA). Details of antibodies in materials and methods.

** HTLV-I gag proteins were detected with an HTLV-I specific mAb (Epitope Inc., OR, USA) by Western blot analysis.
Table 2. Transmission of HTLV-I into newborn rats

<table>
<thead>
<tr>
<th>Strain</th>
<th>Rat MHC</th>
<th>n</th>
<th>Cells injected (1×10^7)</th>
<th>Anti-HTLV-I antibodies *</th>
<th>Presence of HTLV-I provirus genome **</th>
</tr>
</thead>
<tbody>
<tr>
<td>LEW</td>
<td>I</td>
<td>18</td>
<td>LEW-S1</td>
<td>0/18 (0%)</td>
<td>16/18 (89%)</td>
</tr>
<tr>
<td>WKA</td>
<td>k</td>
<td>3</td>
<td>WKA-S1</td>
<td>0/3 (0%)</td>
<td>3/3 (100%)</td>
</tr>
<tr>
<td>LEW</td>
<td>I</td>
<td>8</td>
<td>MT-2</td>
<td>0/8 (0%)</td>
<td>8/8 (100%)</td>
</tr>
<tr>
<td>WKA</td>
<td>k</td>
<td>9</td>
<td>MT-2</td>
<td>0/9 (0%)</td>
<td>8/9 (89%)</td>
</tr>
<tr>
<td>F344</td>
<td>Iv1</td>
<td>20</td>
<td>MT-2</td>
<td>2/20 (10%)</td>
<td>16/20 (80%)</td>
</tr>
<tr>
<td>ACI</td>
<td>av1</td>
<td>8</td>
<td>MT-2</td>
<td>0/8 (0%)</td>
<td>7/8 (88%)</td>
</tr>
</tbody>
</table>

* Anti-HTLV-I antibodies were measured at 1 and 7 months postnatally
** Presence of the HTLV-I provirus genome was determined 4~6 months postnatally
### Table 3. Transmission of HTLV-I into adult rats

<table>
<thead>
<tr>
<th>Strain</th>
<th>Rat MHC RT1</th>
<th>n</th>
<th>Age(weeks) at 1st MT-2 injection *</th>
<th>Anti-HTLV-I antibodies</th>
<th>Presence of HTLV-I provirus genome **</th>
</tr>
</thead>
<tbody>
<tr>
<td>LEW</td>
<td>l</td>
<td>5</td>
<td>16</td>
<td>5/5</td>
<td>5/5</td>
</tr>
<tr>
<td>WKA</td>
<td>k</td>
<td>5</td>
<td>16</td>
<td>5/5</td>
<td>5/5</td>
</tr>
<tr>
<td>F344</td>
<td>Lv1</td>
<td>5</td>
<td>16</td>
<td>5/5</td>
<td>1/1</td>
</tr>
<tr>
<td>ACI</td>
<td>av1</td>
<td>5</td>
<td>16</td>
<td>5/5</td>
<td>5/5</td>
</tr>
<tr>
<td>SDJ</td>
<td>u</td>
<td>5</td>
<td>16</td>
<td>5/5</td>
<td>5/5</td>
</tr>
<tr>
<td>BUF</td>
<td>b</td>
<td>5</td>
<td>16</td>
<td>5/5</td>
<td>5/5</td>
</tr>
<tr>
<td>LEJ</td>
<td>j</td>
<td>5</td>
<td>16</td>
<td>5/5</td>
<td>5/5</td>
</tr>
</tbody>
</table>

* Ten million cells of MT-2 were injected into the tail vein twice at 2 week intervals

** Purified DNA from PBMCs was subjected to PCR amplification at 4 months after injection
<table>
<thead>
<tr>
<th>Rat No.</th>
<th>cerebrum</th>
<th>cerebellum</th>
<th>thymus</th>
<th>heart</th>
<th>lung</th>
<th>liver</th>
<th>kidney</th>
<th>spleen</th>
<th>submandibular gland</th>
<th>Lymphnodes</th>
<th>PBMCs</th>
</tr>
</thead>
<tbody>
<tr>
<td>36</td>
<td>-</td>
<td>-</td>
<td>+</td>
<td>-</td>
<td>+</td>
<td>-</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>128</td>
<td>-</td>
<td>-</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>129</td>
<td>+</td>
<td>-</td>
<td>+</td>
<td>-</td>
<td>-</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>-</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>130</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>-</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>131</td>
<td>+</td>
<td>-</td>
<td>+</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>+</td>
<td>-</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
</tbody>
</table>

Table 4. Tissue distribution of HTLV-I provirus genome in F344 rats
Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Figure 1.
cerebrum
cerebellum
thymus
heart
lung
liver
kidney
spleen
spleen
submandibular gland
lymphnodes
PBMCs
positive control
positive control
positive control
negative control
Figure 3.